article thumbnail

Caprion Becomes CellCarta: CRO Rebrands After Banner Year for Acquisitions and Partnerships

XTalks

The move follows the 2019 merger between Caprion and HistoGeneX , a Belgian histopathology and genomics lab. We wanted to create a brand that is unique in the market, relevant to our clients and inspiring to our employees around the world,” said Nick Wright, president and COO of CellCarta, in a statement about the rebrand. “Our

article thumbnail

Exact Sciences buys cancer detection company Thrive for $2.15 billion

pharmaphorum

Stocks for Exact Sciences leaped 33% after it announced the acquisition of liquid biopsy rival Thrive and UK start-up Base Genomics. The CancerSEEK blood test is designed to detect multiple cancers by analysing tumour specific genomic mutations in circulating tumor DNA (ctDNA) and cancer-associated protein biomarkers in plasma.

Genome 64
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

AI test could predict best cancer therapies for patients

pharmaphorum

The team has focused initially on non-small cell lung cancer (NSCLC), the most common form of lung cancer, but say the same principles could be applied to other tumour types, and combined with other testing approaches like genomics to inform treatment decisions.

Protein 67
article thumbnail

Making a big impact in small patient populations

pharmaphorum

Approximately 85% of rare diseases are genetic, offering significant opportunities to develop better treatments as our understanding of the human genome improves 1. Concentrating on patient identification early in the clinical phases can drive brand loyalty and develop more effective tactics, to address unmet patient needs.

article thumbnail

Pharma Trends: Shaping the Future of Healthcare Marketing

Pharma Marketing Network

As more patients turn to digital platforms for information and brands compete in an increasingly crowded market, pharma marketers need to be agile, creative, and tech-savvy to succeed. Personalized medicine, often driven by genomic data, is revolutionizing how treatments are marketed. How do you keep up?

article thumbnail

Fastest Growing Medical Device/Medtech Companies in 2024

XTalks

Exact Sciences’ Precision Oncology portfolio provides actionable genomic insights to detect cancer earlier and provides guidance for successful treatment following a diagnosis. Exact Sciences is also investing in its pipeline to develop innovative solutions before, during and after a cancer diagnosis.

article thumbnail

Bayer receives approval for Vitrakvi™ in Japan

The Pharma Data

Berlin, March 23, 2021 – Bayer announced today that the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted marketing authorization for larotrectinib, under the brand name Vitrakvi , for the treatment of Neurotrophic Tyrosine Receptor Kinase ( NTRK ) fusion-positive advanced or recurrent solid tumors. Fields, M.D.,

Genome 52